CN101374847A - 雷帕霉素的制备方法 - Google Patents

雷帕霉素的制备方法 Download PDF

Info

Publication number
CN101374847A
CN101374847A CNA2007800034190A CN200780003419A CN101374847A CN 101374847 A CN101374847 A CN 101374847A CN A2007800034190 A CNA2007800034190 A CN A2007800034190A CN 200780003419 A CN200780003419 A CN 200780003419A CN 101374847 A CN101374847 A CN 101374847A
Authority
CN
China
Prior art keywords
formula
compound
alkyl
aryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800034190A
Other languages
English (en)
Chinese (zh)
Inventor
M·阿克莫格鲁
S·普费弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101374847A publication Critical patent/CN101374847A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2007800034190A 2006-01-24 2007-01-22 雷帕霉素的制备方法 Pending CN101374847A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0601406.2A GB0601406D0 (en) 2006-01-24 2006-01-24 Organic Compounds
GB0601406.2 2006-01-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410391783.0A Division CN104211716A (zh) 2006-01-24 2007-01-22 雷帕霉素的制备方法

Publications (1)

Publication Number Publication Date
CN101374847A true CN101374847A (zh) 2009-02-25

Family

ID=36060760

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800034190A Pending CN101374847A (zh) 2006-01-24 2007-01-22 雷帕霉素的制备方法
CN201410391783.0A Pending CN104211716A (zh) 2006-01-24 2007-01-22 雷帕霉素的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410391783.0A Pending CN104211716A (zh) 2006-01-24 2007-01-22 雷帕霉素的制备方法

Country Status (11)

Country Link
US (1) US8138344B2 (enExample)
EP (1) EP1979359A1 (enExample)
JP (2) JP5416412B2 (enExample)
KR (1) KR101423343B1 (enExample)
CN (2) CN101374847A (enExample)
AU (1) AU2007209569B2 (enExample)
BR (1) BRPI0707330A2 (enExample)
CA (1) CA2637075A1 (enExample)
GB (1) GB0601406D0 (enExample)
RU (1) RU2448970C2 (enExample)
WO (1) WO2007085400A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115776907A (zh) * 2020-03-27 2023-03-10 艾奥维安制药公司 Mtorc1调节剂及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
WO2014077577A1 (ko) * 2012-11-13 2014-05-22 엘지전자 주식회사 데이터 전송 방법 및 장치와, 데이터 전송 방법 및 장치
SG10202112135VA (en) 2013-03-15 2021-12-30 Biosensors International Group Ltd Purification of rapamycin derivatives
EP3109250A1 (en) * 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
FI3898637T3 (fi) 2018-12-18 2025-02-24 Novartis Ag Rapamysiinijohdannaisia
AU2020210921B2 (en) 2019-01-22 2022-02-03 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
RU2158267C2 (ru) * 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115776907A (zh) * 2020-03-27 2023-03-10 艾奥维安制药公司 Mtorc1调节剂及其用途

Also Published As

Publication number Publication date
WO2007085400A1 (en) 2007-08-02
JP2009523836A (ja) 2009-06-25
RU2448970C2 (ru) 2012-04-27
US8138344B2 (en) 2012-03-20
RU2008134424A (ru) 2010-02-27
CA2637075A1 (en) 2007-08-02
JP2013136631A (ja) 2013-07-11
BRPI0707330A2 (pt) 2011-05-03
GB0601406D0 (en) 2006-03-08
KR20080090453A (ko) 2008-10-08
AU2007209569B2 (en) 2011-09-15
AU2007209569A1 (en) 2007-08-02
JP5416412B2 (ja) 2014-02-12
CN104211716A (zh) 2014-12-17
US20090012298A1 (en) 2009-01-08
EP1979359A1 (en) 2008-10-15
KR101423343B1 (ko) 2014-07-24

Similar Documents

Publication Publication Date Title
CN101374847A (zh) 雷帕霉素的制备方法
US8884016B2 (en) Apixaban preparation process
US8901322B2 (en) Crystalline forms of cabazitaxel and process for preparation thereof
CA2118171C (en) Galanthamine derivatives, a process for their preparation and their use as medicaments
CA2797999C (en) Process for the preparation of chiral hydrazides
ES2946905T3 (es) Proceso para la preparación de apalutamida
EP3923934A1 (en) Method of preparing a don prodrug from l-pyroglutamic acid
JP2024530795A (ja) ニロガセスタットの合成
US7217822B2 (en) Process for making cabergoline
CN110143934B (zh) 一种含氟紫杉烷类化合物及其制备方法与应用
ES2881899T3 (es) Procedimiento de preparación de un inhibidor de fosfodiesterasa 4
MX2008009469A (en) Process for the preparation of rapamycin derivatives
AU2011254079A1 (en) Process for the preparation of rapamycin derivatives
JP3467265B2 (ja) アゼチジノン化合物の結晶
US6426417B1 (en) Processes and intermediates useful to make antifolates
JP2000095780A (ja) カーバメート体類結晶の製造方法
WO2011077174A1 (en) Process for preparing pharmaceutical compounds and intermediate compounds
JP3495774B2 (ja) １−ヒドロキシインドール類の製法
WO2006080025A1 (en) Process for ziprasidone using novel intermediates
JPS6344757B2 (enExample)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090225